Art

J-GLOBAL ID：201902259752926904   Reference number：19A0714409

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

循環内皮細胞の探索的分析と組み合わせた進行性非扁平上皮非小細胞肺癌患者に対するファーストライン治療としてのベバシズマブ,シスプラチンおよびドセタキセル+維持ベバシズマブの第II相試験:胸部腫瘍学研究グループ(TORG)1016【JST・京大機械翻訳】

Author (22)： Ikeda Satoshi (Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan) ,  Kato Terufumi (Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan) ,  Kato Terufumi (Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan) ,  Ogura Takashi (Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan) ,  Sekine Akimasa (Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan) ,  Oda Tsuneyuki (Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan) ,  Masuda Noriyuki (Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan) ,  Igawa Satoshi (Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan) ,  Katono Ken (Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan) ,  Otani Sakiko (Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan) ,  Yamada Kouzo (Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan) ,  Saito Haruhiro (Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan) ,  Kondo Tetsuro (Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan) ,  Hosomi Yukio (Division of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan) ,  Nakahara Yoshiro (Department of Respiratory Medicine, Kitasato University Hospital, Sagamihara, Japan) ,  Nakahara Yoshiro (Division of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan) ,  Nishikawa Masanori (Department of Respiratory Medicine, Fujisawa City Hospital, Fujisawa, Japan) ,  Utumi Keiko (Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Japan) ,  Misumi Yuki (Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan) ,  Yamanaka Takeharu (Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan) ,  Sakamaki Kentaro (Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan) ,  Okamoto Hiroaki (Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan)
Material： BMC Cancer (Web)
Volume： 18  Issue： 1  Page： 241  Publication year： 2018 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Preclinical studies have demon...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0714409&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： *non-small cell lung cancer ,  effectiveness ,  drug therapy ,  *phase 2 study ,  Hypertension ,  combination therapy ,  Safety ,  forecast ,  Recurrence ,  *human ,  toxicity ,  *platinum complex ,  *antitumor drug ,  *ammine complex ,  *chloro complex ,  adverse reaction ,  aromatic carboxylic acid ,  carbamate ,  oxygen heterocyclic compound ,  bridged compound ,  tetracyclic diterpene ,  carboxylate (ester) ,  hydroxy acid ,  hydroxy ketone ,  polyol
Semi thesaurus term： *cisplatin ,  有害事象 ,  全生存期間 ,  *ベバシズマブ , 【Automatic Indexing@JST】

Author keywords (4)： Non-small cell lung cancer ,  Docetaxel ,  Bevacizumab ,  Circulating endothelial cell

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Gene expression  (EC02040Q)

Substance index (1)： Docetaxel

Reference (37)：

• N Engl J Med; Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer; JH Schiller, D Harrington, CP Belani, C Langer, A Sandler, J Krook; 346; 2002; 92-98; 10.1056/NEJMoa011954; citation_id=CR1
• Mol Biol Cell; Taxol suppresses dynamics of individual microtubules in living human tumor cells; AM Yvon, P Wadsworth, MA Jordan; 10; 1999; 947-959; 10.1091/mbc.10.4.947; citation_id=CR2
• Drugs; Docetaxel: a review of its use in metastatic breast cancer; KA Lyseng-Williamson, C Fenton; 65; 2005; 2513-2531; 10.2165/00003495-200565170-00007; citation_id=CR3
• Drugs; The taxoids. Comparative clinical pharmacology and therapeutic potential; EA Eisenhauer, JB Vermorken; 55; 1998; 5-30; 10.2165/00003495-199855010-00002; citation_id=CR4
• Cancer Res; Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol; N Klauber, S Parangi, E Flynn, E Hamel, RJ D'Amato; 57; 1997; 81-86; citation_id=CR5

Terms in the title (14)： 循環 ,  内皮細胞 ,  探索 ,  分析 ,  非扁平上皮非小細胞肺癌 ,  患者 ,  治療 ,  ベバシズマブ ,  シスプラチン ,  ドセタキセル ,  第II相試験 ,  胸部腫瘍 ,  研究 ,  グループ